Trademark Search  /  NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES

NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES

● Live · Registered

U.S. federal trademark · Serial No. 97296549 · Reg. No. 7064074

Mark
NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES
Status
Registered
Serial Number
97296549
Registration No.
7064074
Filing Date
March 4, 2022
Registration Date
May 23, 2023
Class(es)
Class 042

Owners

Angiex, Inc.
03 · Cambridge, MA, US
Angiex, Inc.
03 · Cambridge, MA, US

Goods & Services

Scientific research and development in the fields of cancer, immunological-inflammatory conditions, tissue repair, eye diseases, cardiovascular disease, biology, laboratory testing, biotechnology, biochemistry, and medicine; research and product development services for others in the fields of cancer, immunological-inflammatory conditions, tissue repair, eye diseases, cardiovascular disease, biology, laboratory testing, biotechnology, biochemistry, and medicine; Medical and scientific research in the fields of cancer, immunological-inflammatory conditions, tissue repair, eye diseases, and cardiovascular disease detection; Providing information on the subject of scientific research in the fields of cancer, immunological-inflammatory conditions, tissue repair, eye diseases, cardiovascular disease, biology, laboratory testing, biotechnology, biochemistry, and medicine

Thinking of using a similar name?
Search 14 million+ trademarks free and see if your brand conflicts with "NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES" or anything like it, before you file.
Run a free trademark search →

Source: USPTO federal trademark records. Informational only, not legal advice. Status and details may lag the live USPTO database.